Syncom Formulations (India) Ltd Falls to 52-Week Low Amid Market Downturn

Stock Price Movement and Market Context

On 20 Jan 2026, Syncom Formulations (India) Ltd’s stock price declined by 2.37% to reach Rs.12.3, its lowest level in the past year. This drop comes after two consecutive days of losses, during which the stock has fallen by 4.47%. The share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.

In comparison, the broader Sensex index opened flat but later declined by 320.54 points, or 0.43%, closing at 82,886.84. Despite this, the Sensex remains only 3.95% below its 52-week high of 86,159.02. The index has experienced a three-week consecutive fall, losing 3.35% over this period. While the Sensex trades below its 50-day moving average, the 50DMA remains above the 200DMA, indicating mixed technical signals for the broader market.

Syncom Formulations’ underperformance is notable when compared to the Sensex’s 7.51% gain over the past year. The stock has declined by 34.71% during the same period, reflecting challenges specific to the company and its sector.

Financial Performance and Valuation Metrics

Syncom Formulations operates within the Pharmaceuticals & Biotechnology sector and currently holds a Mojo Score of 46.0, with a Mojo Grade of Sell, downgraded from Hold as of 1 Aug 2025. The company’s market capitalisation grade stands at 3, reflecting its mid-cap status.

Over the last five years, the company has experienced a decline in net sales at an annualised rate of -63.63%, alongside a contraction in operating profit by -52.27%. These figures highlight a challenging growth trajectory over the medium term. Despite this, the company has demonstrated some recent improvements in profitability metrics.

In the latest six-month period, Syncom Formulations reported net sales of Rs.238.62 crores, growing by 25.87%, while profit after tax (PAT) surged by 72.46% to Rs.32.32 crores. Operating profit also increased by 8.29%, contributing to six consecutive quarters of positive results. The company’s return on capital employed (ROCE) for the half year reached a high of 22.06%, and return on equity (ROE) stands at 16.6%, indicating efficient utilisation of capital.

Valuation metrics show the stock trading at a price-to-book value of 3.1, which is a premium relative to its peers’ historical averages. The company’s PEG ratio is 0.2, reflecting the relationship between its price-to-earnings ratio and earnings growth rate. Despite the recent price decline, profits have risen by 90.1% over the past year, underscoring a disconnect between earnings performance and share price movement.

Shareholding and Market Sentiment

Domestic mutual funds currently hold no stake in Syncom Formulations, a factor that may reflect limited institutional confidence or interest at prevailing price levels. Given that domestic mutual funds typically conduct thorough research and maintain positions in companies with favourable prospects, their absence from the shareholding pattern is noteworthy.

The stock’s recent underperformance relative to the BSE500 index, which generated returns of 6.09% over the last year, further emphasises the challenges faced by Syncom Formulations in attracting broader market support.

Balance Sheet and Debt Position

On a positive note, the company maintains a low average debt-to-equity ratio of 0.05 times, indicating a conservative capital structure with limited leverage. This low debt level reduces financial risk and provides some stability amid fluctuating market conditions.

Sector and Peer Comparison

Within the Pharmaceuticals & Biotechnology sector, Syncom Formulations’ recent price performance contrasts with the broader market trends. While the sector has faced volatility, the company’s share price decline to Rs.12.3 represents a significant deviation from its 52-week high of Rs.23.46, a drop of nearly 47.5%. This decline is sharper than many peers, reflecting company-specific factors influencing investor sentiment.

The stock’s current Mojo Grade of Sell, downgraded from Hold, aligns with its relative underperformance and subdued growth metrics. The company’s market capitalisation grade of 3 places it in the mid-cap category, where volatility can be more pronounced compared to large-cap stocks.

Summary of Key Metrics

To summarise, Syncom Formulations (India) Ltd’s key financial and market indicators as of 20 Jan 2026 are:

• New 52-week low price: Rs.12.3


• Price decline over last 2 days: -4.47%


• Mojo Score: 46.0 (Sell grade)


• Market Cap Grade: 3 (Mid Cap)


• Net Sales growth (5 years annualised): -63.63%


• Operating Profit growth (5 years annualised): -52.27%


• Latest 6 months PAT growth: 72.46% (Rs.32.32 crores)


• Latest 6 months Net Sales growth: 25.87% (Rs.238.62 crores)


• ROCE (Half Year): 22.06%


• ROE: 16.6%


• Debt to Equity ratio (average): 0.05 times


• Price to Book Value: 3.1


• PEG Ratio: 0.2

These figures illustrate a complex picture where recent profitability improvements coexist with longer-term sales and operating profit declines, contributing to the current subdued market valuation.

Technical and Market Indicators

The stock’s trading below all major moving averages signals a bearish technical stance. This is compounded by the broader market’s recent weakness, with the Sensex experiencing a three-week decline. However, the Sensex’s proximity to its 52-week high and the positive positioning of its 50DMA above the 200DMA suggest that market conditions remain fluid.

Syncom Formulations’ relative underperformance against the Sensex and BSE500 indices highlights the challenges the company faces in regaining investor confidence and market momentum.

Conclusion

Syncom Formulations (India) Ltd’s fall to a 52-week low of Rs.12.3 reflects a combination of subdued long-term growth, recent price weakness, and cautious market sentiment. While recent financial results show encouraging profit growth and a strong return on capital, these have yet to translate into sustained share price recovery. The stock’s current valuation metrics and technical indicators underscore the ongoing challenges within the Pharmaceuticals & Biotechnology sector and the company’s specific market positioning.

Unlock special upgrade rates for a limited period. Start Saving Now →